Sutro Biopharma (STRO) Total Debt (2017 - 2023)
Sutro Biopharma (STRO) posted Total Debt of $4.1 million for Q4 2023, down 43.1% sequentially from $7.1 million in Q3 2023, and down 75.04% YoY from $16.3 million in Q4 2022.
Sutro Biopharma (STRO) Total Debt (2017 - 2023) Analysis & Trends
Sutro Biopharma has reported Total Debt for 7 years, with the latest figure at $4.1 million in Q4 2023.
- Quarterly Total Debt fell 75.04% year-over-year to $4.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.1 million (down 75.04% YoY) and the FY2023 annual result came in at $4.1 million, down 75.04% from the prior year.
- Total Debt retreated to $4.1 million in Q4 2023 per STRO's latest filing, from $7.1 million in the prior quarter.
- Over five years, Total Debt peaked at $25.3 million in Q1 2022 and troughed at $4.1 million in Q4 2023.
- A 5-year average of $18.1 million and a median of $20.8 million in 2022 frame the typical range for Total Debt.
- The sharpest annual moves came in 2020 and 2023: Total Debt soared 148.53% in 2020, then slumped 75.04% in 2023.
- Over 5 years, Total Debt stood at $9.9 million in 2019, then jumped by 148.53% to $24.5 million in 2020, then climbed by 2.31% to $25.1 million in 2021, then plunged by 35.21% to $16.3 million in 2022, then plunged by 75.04% to $4.1 million in 2023.
- According to Business Quant data, Total Debt over the past three periods registered $4.1 million, $7.1 million, and $10.2 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.06 Mn |
| Sep 30, 2023 | 7.14 Mn |
| Jun 30, 2023 | 10.20 Mn |
| Mar 31, 2023 | 13.24 Mn |
| Dec 31, 2022 | 16.27 Mn |
| Sep 30, 2022 | 19.28 Mn |
| Jun 30, 2022 | 22.28 Mn |
| Mar 31, 2022 | 25.26 Mn |
| Dec 31, 2021 | 25.11 Mn |
| Sep 30, 2021 | 24.96 Mn |
| Jun 30, 2021 | 24.82 Mn |
| Mar 31, 2021 | 24.68 Mn |
| Dec 31, 2020 | 24.55 Mn |
| Sep 30, 2020 | 24.41 Mn |
| Jun 30, 2020 | 24.28 Mn |
| Mar 31, 2020 | 24.16 Mn |
| Dec 31, 2019 | 9.88 Mn |
| Sep 30, 2019 | 11.34 Mn |
| Jun 30, 2019 | 12.81 Mn |
| Mar 31, 2019 | 14.27 Mn |